Clinical outcomes and bioprosthetic valve function after transcatheter aortic valve implantation under dual antiplatelet therapy vs. Aspirin alone

Circulation Journal

Volumn 81, Issue 3, 2017, Pages 397-404

  Ichibori, Yasuhiro ^a   Mizote, Isamu ^a   Maeda, Koichi ^a   Onishi, Toshinari ^a   Ohtani, Tomohito ^a   Yamaguchi, Osamu ^a   Torikai, Kei ^a   Kuratani, Toru ^a   Sawa, Yoshiki ^a   Nakatani, Satoshi ^a   Sakata, Yasushi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antithrombotic therapy; Aspirin alone; Dual antiplatelet therapy; Transcatheter aortic valve implantation

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; OMEPRAZOLE; TICLOPIDINE; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR PARAMETERS; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DUAL ANTIPLATELET THERAPY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART TAMPONADE; HEART VALVE BIOPROSTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PLEURA EFFUSION; PRESSURE GRADIENT; RETROSPECTIVE STUDY; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSTHORACIC ECHOCARDIOGRAPHY; TRANSVALVULAR PRESSURE GRADIENT; VERY ELDERLY; AORTA VALVE; AORTIC VALVE STENOSIS; BIOPROSTHESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEART VALVE PROSTHESIS; MORTALITY; SURGERY; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; AORTIC VALVE; AORTIC VALVE STENOSIS; ASPIRIN; BIOPROSTHESIS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; SURVIVAL RATE; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 85013991162     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-16-0903     Document Type: Article

References (25)

1. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): A randomized controlled trial. Lancet 2015; 385: 2477-2484.
2. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): A randomized controlled trial. Lancet 2015; 385: 2485-2491.
3. Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, et al. Outcomes after transcatheter aortic valve replacement using a novel balloon-expandable transcatheter heart valve: A single-center experience. JACC Cardiovasc Interv 2015; 8: 1809-1816.
4. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370: 1790-1798.
5. Maeda K, Kuratani T, Torikai K, Mizote I, Ichibori Y, Onishi T, et al. New self-expanding transcatheter aortic valve device for transfemoral implantation: Early results of the first-in-Asia implantation of the ACURATE Neo/TF(TM) system. Circ J 2015; 79: 1037-1043.
6. Kodali S, Thourani VH, White J, Malaisrie SC, Lim S, Greason KL, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J 2016; 37: 2252-2262.
7. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33: 2451-2496.
8. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: e521-e643.
9. Sawa Y, Saito S, Kobayashi J, Niinami H, Kuratani T, Maeda K, et al. First clinical trial of a self-expandable transcatheter heart valve in Japan in patients with symptomatic severe aortic stenosis. Circ J 2014; 78: 1083-1090.
10. Sawa Y, Takayama M, Mitsudo K, Nanto S, Takanashi S, Komiya T, et al. Clinical efficacy of transcatheter aortic valve replacement for severe aortic stenosis in high-risk patients: The PREVAIL JAPAN trial. Surg Today 2015; 45: 34-43.
11. Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, et al; for the Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study. Stroke 2008; 39: 1740-1745.
12. Maeda K, Kuratani T, Torikai K, Ichibori Y, Nakatani K, Onishi T, et al. Early outcomes in Japanese dialysis patients treated with transcatheter aortic valve implantation. Circ J 2015; 79: 2713-2719.
13. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 Consensus Document (VARC-2). J Am Coll Cardiol 2012; 60: 1438-1454.
14. Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, et al. Duration of dual antiplatelet therapy and longterm clinical outcome after coronary drug-eluting stent implantation: Landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. Circ Cardiovasc Interv 2012; 5: 381-391.
15. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 49: 1362-1368.
16. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
17. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005; 165: 784-789.
18. Nombela-Franco L, Webb JG, de Jaegere PP, Toggweiler S, Nuis RJ, Dager AE, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation 2012; 126: 3041-3053.
19. Tay EL, Gurvitch R, Wijesinghe N, Nietlispach F, Wood D, Cheung A, et al. A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2011; 4: 1290-1297.
20. Cota L, Stabile E, Agrusta M, Sorropago G, Pucciarelli A, Ambrosini V, et al. Bio- prostheses “thrombosis” after transcatheter aortic valve replacement. J Am Coll Cardiol 2013; 61: 789-791.
21. De Marchena E, Mesa J, Pomenti S, Marin Y Kall C, Marincic X, Yahagi K, et al. Thrombus formation following transcatheter aortic valve replacement. JACC Cardiovasc Interv 2015; 8: 728-739.
22. Stabile E, Pucciarelli A, Cota L, Sorropago G, Tesorio T, Salemme L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: A pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014; 174: 624-627.
23. Ussia GP, Scarabelli M, Mulè M, Barbanti M, Sarkar K, Cammalleri V, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108: 1772-1776.
24. Durand E, Blanchard D, Chassaing S, Gilard M, Laskar M, Borz B, et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014; 113: 355-360.
25. Maeda K, Kuratani T, Torikai K, Shimamura K, Mizote I, Ichibori Y, et al. Impact of electrocardiogram-gated multi-slice computed tomography-based aortic annular measurement in the evaluation of paravalvular leakage following transcatheter aortic valve replacement: The efficacy of the OverSized AortiC Annular ratio (OSACA ratio) in TAVR. J Card Surg 2013; 28: 373-379.